当前位置:首页 > 报告详情

LifeArc 资助者演讲.pdf

上传人: 芦苇 编号:1146343 2026-02-14 6页 768.47KB

1、Peter CoombsMRC CMM Partnerships SummitLifeArcDiscoveryLate translationPost-academia,pre-venture capital,proof of conceptDesigning molecules/assaysNavigating developmentProtecting innovationMarket approvalEarly translationPre-and early clinical trialsClinical proof of conceptRegulatory submissionsBu

2、ilding cohortsDemonstrating safety and efficacyOur focus&goalsWe focus on rare diseases&Global HealthGoalsCollaborate across sectors and bordersDevelop treatments&diagnosticsCoordinate efforts to improve policies and regulationWe help promising scientific ideas reach the next phase of development th

3、rough investment,partnerships and expertise for health conditions that need it mostGlobal Health Global Health-Infection Translational ChallengeAt least 2 billion people globally are currently affected by infectious diseases,with disproportionate mortality and morbidity in low resource settingsOur p

4、otential for impact:Faster&sustainable innovation translationOptimized patient outcomesa reduction in mortality and morbidity from infectionsPrevent and control drug-resistant infections in highly impacted populationsASPIRECollaboration with ReAct Africa that aims to transform the use of antibiotics

5、 in hospitals in Zambia and KenyaLifeArc funding is supporting a surveillance and stewardship program aided by the development of innovative digital solutionsCrick Africa NetworkCollaboration with The Francis Crick Institute supporting Career Acceleration Fellowships in AfricaLifeArc will provide fu

6、nding,scientific mentorship and training in commercialisation and leadershipAfrica Drug Discovery AcceleratorCo-funding with the Gates Foundation Grand Challenges to African research institutes for 3-year drug discovery programs LifeArc provides funding,techni

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **定位与目标**:LifeArc聚焦罕见病及全球健康,通过投资、合作与专业知识,推动科研概念进入下一阶段(从学术后到风投前,从临床前到市场批准)。 2. **全球健康挑战**:全球超20亿人受传染病影响,资源匮乏地区死亡率与发病率更高,需加速创新转化、优化患者结局、降低感染死亡率及耐药性。 3. **关键合作项目**: - **ASPIRE**:与ReActAfrica合作,在赞比亚、肯尼亚推动医院抗生素合理使用,开发数字解决方案。 - **Africa Drug Discovery Accelerator**:与盖茨基金会共同资助非洲研究所3年药物发现项目。 - **DOSA**:与爱丁堡大学合作,开发印度社区快速诊断工具(如UTI检测试条)。 4. **真菌病关注**:将耐药性真菌感染视为全球威胁,参与PACE(3000万英镑)、肺健康与感染创新中心(1500万英镑)等项目,推动诊断与治疗创新。
**罕见病合作?** *LifeArc如何通过跨部门合作推动罕见病治疗开发?* **感染病挑战?** *全球20亿人受感染病影响,LifeArc如何应对耐药性危机?* **真菌威胁?** *真菌疾病成全球健康隐患,LifeArc有哪些创新解决方案?*
客服
商务合作
小程序
服务号
折叠